Skip to main content
SpringerLink
Log in

The Australian Guidelines for Subsidisation of Pharmaceuticals

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

An Erratum to this article was published on 01 January 1993

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Evans D, Freund D, Dittus R, Robertson J, Henry D. The use of economic analysis as a basis for inclusion of pharmaceutical products on the Pharmaceutical Benefits Scheme. Department of Health, Housing and Community services, Commonwealth of Australia, Canberra, 1990

    Google Scholar 

  • Henry D. Economic analysis as an aid to subsidisation decisions. The development of Australian Guidelines for Pharmaceuticals. PharmacoEconomics 1: 54–67, 1992

    Article  PubMed  CAS  Google Scholar 

  • Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991

    Article  PubMed  CAS  Google Scholar 

  • Johannesson M. The Australian guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing? PharmacoEconomics 2: 355–362, 1992

    Article  PubMed  CAS  Google Scholar 

  • Mitchell A, Henry D. Potential for bias in economic analyses. New England Journal of Medicine 325: 1384, 1991

    Google Scholar 

References

  • Henry D. Letter to the Editor. PharmacoEconomics 2: 422–424, 1992

    Article  PubMed  CAS  Google Scholar 

  • Johannesson M. The Australian guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing? PharmacoEconomics 2: 355–362, 1992

    Article  PubMed  CAS  Google Scholar 

  • Ontario Ministry of Health. Guidelines for preparation of economic analysis to be included in submission to drug programs branch for listing in the Ontario drug benefit formulary/comparative drug index. Drug Programme Branch. Ministry of Health, Toronto, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Newcastle, Newcastle, Australia

    David A. Henry (Senior Lecturer in Clinical Pharmacology)

  2. Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden

    Magnus Johannesson

  3. Department of Health Policy and Management, Harvard School of Public Health, Boston, USA

    Magnus Johannesson

Authors
  1. David A. Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Magnus Johannesson
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03260130.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Henry, D.A., Johannesson, M. The Australian Guidelines for Subsidisation of Pharmaceuticals. PharmacoEconomics 2, 422–426 (1992). https://doi.org/10.2165/00019053-199202050-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199202050-00010

Keywords

Search

Navigation